Global Ingredient Risk Index Metabolic

L-Proline

L-Proline

Also known as: proline, L-proline, hydroxyproline precursor

25 მარ 2026

LOW RISK 2.0/10 How?

This ingredient is classified as unclassified risk (GIRI score: 2.0/10).

Known Safety Concerns

Very limited human safety data for isolated supplementation
No established UL
Proline imino acid structure -- rare metabolic disorders involve proline metabolism
Generally considered safe

Contraindications

Very limited human safety data for isolated supplementation
No established UL

═══════════════════════════════════════════════════════════════════════ -->

Information not yet available for this ingredient profile.

L-proline is a non-essential amino acid critical for collagen and connective tissue synthesis. Used in joint health and skin supplements. Well tolerated with very limited adverse event documentation. No established UL.

Scientific Name: L-Proline

Information not yet available for this ingredient profile.

SETI Score 50/100

Risk Level High risk

Scientific Confidence Low

Evidence Strength Limited

Key Benefit Metabolic

Key Safety Concern Very limited human safety data for isolated supplementation

Evidence Reviewed 10 PubMed studies

Scientific Confidence Low

Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100

Risk Level High risk

Evidence Strength Limited

Main Benefit Metabolic

Main Safety Concern Very limited human safety data for isolated supplementation

Ingredient L-Proline

Scientific name L-Proline

Scientific Evidence Overview

10 studies reviewed
0 high-quality studies (meta-analysis or RCT)
Main clinical benefit observed: Metabolic
Evidence consistency: High consistency across studies (100%)

Safety Signals

Very limited human safety data for isolated supplementation
No established UL
Proline imino acid structure -- rare metabolic disorders involve proline metabolism
Generally considered safe

Evidence Strength Limited

Final Scientific Assessment

The available scientific evidence for L-Proline indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient L-Proline

Evidence reviewed 10 peer-reviewed studies (last 10 years)

Scientific name L-Proline

50 /100

Total SETI Score

High risk

Evidence quality	10/40
Evidence consistency	20/20
Safety signals	0/20
Study recency	10/10
Evidence transparency	10/10

Evidence Summary

10 studies reviewed
0 high-quality studies (meta-analysis or systematic review)
0 studies identified benefits or no safety concern (GREEN)
10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 25 მარ 2026, 12:51

Evidence Distribution

10 Other / unclassified

Observational / other LOW evidence YELLOW
Synergic Effect of Enzyme-Assisted Extraction and Natural Deep Eutectic Solvents for Bioactives Recovery in Orange Peel Waste. ↗

PMID 41873141 ↗

Journal Biotechnol Appl Biochem

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41873141/

Gomez-Urios C et al.. Synergic Effect of Enzyme-Assisted Extraction and Natural Deep Eutectic Solvents for Bioactives Recovery in Orange Peel Waste.. Biotechnol Appl Biochem. 2026. PMID:41873141.
Observational / other LOW evidence YELLOW
One-pot multicomponent diastereoselective synthesis of indoline spirobicyclics using a recyclable chiral nanomagnetic L-proline catalyst under mild conditions. ↗

PMID 41865026 ↗

Journal Sci Rep

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41865026/

Rafipour D et al.. One-pot multicomponent diastereoselective synthesis of indoline spirobicyclics using a recyclable chiral nanomagnetic L-proline catalyst under mild conditions.. Sci Rep. 2026. PMID:41865026.
Observational / other LOW evidence YELLOW
Determination of proline enantiomers in honey by FMOC-LC/FL and storage-associated changes in enantiomeric composition. ↗

PMID 41844552 ↗

Journal J AOAC Int

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41844552/

Saito K et al.. Determination of proline enantiomers in honey by FMOC-LC/FL and storage-associated changes in enantiomeric composition.. J AOAC Int. 2026. PMID:41844552.
Observational / other LOW evidence YELLOW
Polymerization Chaperone for the Controlled, Homogeneous Synthesis of Proline-Based Homo- and Copolypeptides. ↗

PMID 41834376 ↗

Journal J Am Chem Soc

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41834376/

Lu M et al.. Polymerization Chaperone for the Controlled, Homogeneous Synthesis of Proline-Based Homo- and Copolypeptides.. J Am Chem Soc. 2026. PMID:41834376.
Observational / other LOW evidence YELLOW
Unveiling aggregation-induced emission in benzimidazole-acrylonitriles for fluorescence live-cell imaging in HeLa cells. ↗

PMID 41823225 ↗

Journal J Mater Chem B

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41823225/

Chandrakanth M et al.. Unveiling aggregation-induced emission in benzimidazole-acrylonitriles for fluorescence live-cell imaging in HeLa cells.. J Mater Chem B. 2026. PMID:41823225.
Observational / other LOW evidence YELLOW
A metabolomics approach to fingerprint the heat-induced alterations in milk and identify potential thermal biomarkers. ↗

PMID 41819916 ↗

Journal Food Res Int

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41819916/

Rahman A et al.. A metabolomics approach to fingerprint the heat-induced alterations in milk and identify potential thermal biomarkers.. Food Res Int. 2026. PMID:41819916.
Observational / other LOW evidence YELLOW
Discovery of Pyrazolo[5,1-b]quinazoline Tethered 1,2,3-Triazole Analogs as Potential Antioxidant Agents: Design, Synthesis, Biological Evaluation, and In Silico Insights. ↗

PMID 41819483 ↗

Journal ChemMedChem

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41819483/

Patel RC et al.. Discovery of Pyrazolo[5,1-b]quinazoline Tethered 1,2,3-Triazole Analogs as Potential Antioxidant Agents: Design, Synthesis, Biological Evaluation, and In Silico Insights.. ChemMedChem. 2026. PMID:41819483.
Observational / other LOW evidence YELLOW
Green synthesis of 4,4'-diaminotriarylmethane derivatives using a recyclable magnetic acidic nano catalyst. ↗

PMID 41803296 ↗

Journal Sci Rep

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41803296/

Karamifar S et al.. Green synthesis of 4,4'-diaminotriarylmethane derivatives using a recyclable magnetic acidic nano catalyst.. Sci Rep. 2026. PMID:41803296.
Observational / other LOW evidence YELLOW
Nitrogen and Sulfur Co-Doped Fluorescent Carbon Dots Constructing PVA@N, S-CDs Composite Film: A Next-Generation Food Packaging Material With Dual Functions of Chlortetracycline… ↗

PMID 41797688 ↗

Journal Small

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41797688/

Liu Y et al.. Nitrogen and Sulfur Co-Doped Fluorescent Carbon Dots Constructing PVA@N, S-CDs Composite Film: A Next-Generation Food Packaging Material With Dual Functions of Chlortetracycline Detection and Ultraviolet Shielding.. Small. 2026. PMID:41797688.
Observational / other LOW evidence YELLOW
Stereoselective Preparation of (4S)-1-Methyl-4-Propyl-L-Proline Commencing from (cis)-4-Hydroxy-L-Proline. ↗

PMID 41798737 ↗

Journal Molbank

Year 2025

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41798737/

Mandal GH et al.. Stereoselective Preparation of (4S)-1-Methyl-4-Propyl-L-Proline Commencing from (cis)-4-Hydroxy-L-Proline.. Molbank. 2025. PMID:41798737.

Q × L × D × S × 10 = 2.0 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

Benefit

Risk

50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 2.0 / 10

Final GIRI Score for L-Proline. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.

LOW RISK 2.0/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0

MODERATE
3.0–5.5

HIGH
5.5–7.5

CRITICAL
7.5–10

2.0

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for L-Proline

A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

0 approved references.

Limited — mostly case reports or animal studies (Level 4–5).

Neutral or mixed — benefit and risk signals roughly balanced.

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

Level	Score	Meaning
LOW	0.0 – 2.9	Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE	3.0 – 5.4	Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH	5.5 – 7.4	Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL	7.5 – 10	Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

L-Proline

Safety Profile

Known Safety Concerns

Contraindications

Interactions

Evidence and Scientific Findings

Ingredient Overview

Biological and Chemical Classification

Mechanism of Action

Clinical Evidence of Effectiveness

Pharmacokinetics

Recommended Dosage

SETI — Scientific Evidence Transparency Index

Executive Summary — Ingredient Assessment

Evidence Summary

Evidence Policy

Evidence Distribution

Score Transparency

Risk Level Classification

What drove the Low classification for L-Proline

ბოლო სიახლეები

500მლ პლასტმასის წყლის ბოთლები: ფარული საზოგადოებრივი ჯანმრთელობის რისკები

სკოლამდელი განათლება – მნიშვნელობა და გამოწვევები

ბავშვის უფლებები სკოლაში

პოპულარული ამბები

საუკეთესო ფილმები კულინარიის მოყვარულებისთვის

როგორ იყენებენ ახალგაზრდები ხელოვნურ ინტელექტს – სტუდენტების ხმა

კატეგორიები

ჩვენ შესახებ

გამოგვყევი სოციალურ ქსელებში